- Dengue treatment, encompassing supportive care and symptomatic relief for patients infected with the dengue virus, plays a crucial role in managing this mosquito-borne tropical disease, particularly in endemic regions where recurrent outbreaks strain public health systems
- The rising incidence of dengue globally, fueled by climate change, urbanization, and inadequate vector control, is a primary driver of the dengue treatment market, with increasing government efforts and awareness campaigns also contributing to demand for rapid diagnostics, fluid therapy, and antiviral research
- Asia Pacific dominated the dengue treatment market with the largest revenue share of 58.8% in 2024, characterized by high disease burden, large population base, and ongoing public health initiatives in countries such as India, Indonesia, and the Philippines, where outbreaks frequently result in increased healthcare resource utilization
- Latin America is expected to be the fastest growing region in the dengue treatment market during the forecast period due to improved disease surveillance systems, rising healthcare expenditure, and the development of new vaccine programs and hospital preparedness strategies
- DENV-2 segment dominated the dengue treatment market with a market share of 35.1% in 2024, driven by its higher virulence and prevalence in severe dengue cases across Asia and Latin America
